Some postmenopausal women with breast cancer do not benefit from chemotherapy when it’s added to hormone therapy, according to initial results of a clinical trial.
The findings apply to postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low.
The findings may save tens of thousands of postmenopausal women each year the time, money, and harmful side effects that come with chemotherapy infusions.
This is the first evidence in a randomized phase III trial that postmenopausal women with HR-positive, HER2-negative breast cancer that has spread to one to three lymph nodes can safely forgo chemotherapy if their recurrence score on a genomic tumor tissue test is 25 or less.
New Data at SABCS 2020 Highlight the Role of the Oncotype DX Breast Recurrence Score® Test in Shaping Clinical Practice
- Five-year outcomes from large, prospective phase III ADAPT study confirm value of the test to help guide treatment decisions in breast cancer patients with high clinical risk, including those with node-positive disease
- New meta-analysis of data from more than 10,000 patients with node-negative disease, including the results of TAILORx, supports the Oncotype DX Breast Recurrence Score® test as the standard of care genomic test in early-stage, invasive breast cancer
News provided by
Share this article
MADISON, Wis., Dec. 11, 2020 /PRNewswire/
Breast Cancer Survival Disparities: Need to Address Obesity medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.